Get the Stockscreener App
2.64
11.39%
0.27
Cardiff Oncology Inc stock is traded at $2.64, with a volume of 5.86M.
It is up +11.39% in the last 24 hours and down -24.79% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
See More
Previous Close:
$2.37
Open:
$2.46
24h Volume:
5.86M
Relative Volume:
3.53
Market Cap:
$175.63M
Revenue:
$488.00K
Net Income/Loss:
$-41.44M
P/E Ratio:
-2.8387
EPS:
-0.93
Net Cash Flow:
$-31.47M
1W Performance:
-33.50%
1M Performance:
-24.79%
6M Performance:
-34.49%
1Y Performance:
+14.29%
1-Day Range:
$2.3901
$2.79
1-Week Range:
$2.31
$4.103
52-Week Range:
$2.01
$5.6395
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.64 | 157.67M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Jun-24-25 | Initiated | Jefferies | Hold |
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data? - inkl
Cardiff Oncology Insiders Land Bargain With Gains Of US$244k - Yahoo Finance
Cardiff Oncology: Data Update Resolves Some Signals - Seeking Alpha
Cardiff Oncology (CRDF.O) Plummets 27%: What's Behind the Sharp Intraday Move? - AInvest
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Cardiff Oncology Shares Slide Over 26% In Premarket Trading After Mixed Q2 - Benzinga
Cardiff Oncology Plunges 26.59% on Earnings Miss - AInvest
Cardiff Oncology 2025 Q2 Earnings Financial Struggles as Net Income Declines 18.4% - AInvest
Cardiff Oncology Reports Q2 2025 Financial Results - TipRanks
Cardiff Oncology shares fall 26.89% after-hours after reporting a wider Q2 net loss. - AInvest
Cardiff Oncology shares plunge after Q2 earnings miss By Investing.com - Investing.com South Africa
Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Cardiff Oncology: Q2 Earnings Snapshot - San Francisco Chronicle
Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com
Cardiff Oncology reports results from colorectal cancer trial - Seeking Alpha
Cardiff Oncology reports positive data from colorectal cancer trial By Investing.com - Investing.com Nigeria
Cardiff Oncology reports positive data from colorectal cancer trial - Investing.com Australia
Cardiff Oncology Announces Positive Data from Ongoing Randomized - GuruFocus
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update - GlobeNewswire
Breakthrough: New Cancer Drug Achieves 49% Response Rate vs 30% Standard Care in Colorectal Cancer Trial - Stock Titan
Clinical Trial Success: Cardiff Oncology Advances Colorectal Cancer Treatment with 40% Response Rate - Stock Titan
How Cardiff Oncology Inc. stock performs during market volatilityOversold Stock Bounce Playbook Generator - Newser
Is Cardiff Oncology Inc. stock a growth or value playFree Growth Based Stock Signal Screener - Newser
Is Cardiff Oncology Inc. Stock Overbought or Oversold RSI Indicator AnalysisReal Trader Watchlist with Entry Targets - Newser
Pancreatic Ductal Adenocarcinoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix - Barchart.com
What catalysts could drive Cardiff Oncology Inc. stock higher in 2025Achieve rapid financial growth with expert picks - jammulinksnews.com
How volatile is Cardiff Oncology Inc. stock compared to the marketGet alerts on the hottest market movers - jammulinksnews.com
What is the risk reward ratio of investing in Cardiff Oncology Inc. stockBuild a portfolio that outperforms the market - jammulinksnews.com
How strong is Cardiff Oncology Inc. company’s balance sheetUnlock superior stock analysis tools - jammulinksnews.com
Why is Cardiff Oncology Inc. stock attracting strong analyst attentionAchieve consistent profits with proven methods - jammulinksnews.com
Should I hold or sell Cardiff Oncology Inc. stock in 2025Free Stock Index Interpretation - jammulinksnews.com
When is Cardiff Oncology Inc. stock expected to show significant growthRealize exceptional returns through smart trading - jammulinksnews.com
New Product Launches: Will They Boost Cardiff Oncology Inc. Stock in 2025Free Investment Portfolio Suggestions - Newser
How Interest Rate Changes Impact Cardiff Oncology Inc. Stock PerformanceFree Join Group - Newser
Cardiff Oncology Inc. Company’s Quarterly Earnings Growth: What the Numbers SayProfit Focused Trade Alerts - Newser
Is Cardiff Oncology Inc. a good long term investmentHigh-octane investment gains - PrintWeekIndia
Published on: 2025-07-25 15:19:32 - PrintWeekIndia
What analysts say about Cardiff Oncology Inc. stockExplosive capital appreciation - Autocar Professional
Cardiff Oncology Inc. Stock Analysis and ForecastExplosive trading opportunities - Autocar Professional
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):